Home >> Report Store >> Healthcare >> Anxiety Disorders Treatment Market Report >

Anxiety Disorders Treatment Market Size Worth $18.2 Billion By 2025 | CAGR: 2.2%

Published Date : 25 / 07 / 17  | Report Format: PDF

The global anxiety disorder therapeutics market is expected to grow at growth rate of 2.2% to reach USD 18,234 million by 2025.

According to the World Health Organization (WHO), depression is the second-leading cause of disabilities, affecting more than 300 million populations across the globe. Thus, increasing prevalence of anxiety disorders such as depression has boosted the demand for effective treatment options, augmenting the market growth. Furthermore, raising awareness campaigns regarding anxiety disorders by the government or non-government bodies drive the industry growth. For instance, Anxiety and Depression Association of America (ADAA) started initiative named “BreaktheStigma”. This initiative is focused on raising awareness about anxiety and depression.

Other factors such as new product developments and a growing number of companies investing in this market augment the growth significantly. However, patent expiry of major drugs has slow down the industry development since the last couple of years. For instance, Eli Lilly’s duloxetine delayed-release capsule (i.e. Cymbalta) for depression treatment has lost patent exclusivity in 2014. Owing to this, the revenue was declined significantly during the same period. In 2014, the company posted USD 1,614.7 million sales from Cymbalta, around 63% decrease compared to the previous year (USD 5,084.4 in 2014).

Key Takeaways:

  • Of the drug category, Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) and Serotonin Reuptake Inhibitors (SSRIs) achieved the highest revenue share. In 2017, these segments recorded more than 60% revenue share collectively. The boost in demand for anxiety therapeutics coupled with the rising in a number of companies investing to develop new anxiety drugs drives the market revenue.
  • The study further includes a detailed analysis of top-selling anxiety therapeutics such as Abilify, Cymbalta, Lyrica, Vyvanse among others.
  • On contrary, anxiety therapies are growing with the highest CAGR of 3.7% owing to high efficiency in treating anxiety-related disorders and rising demand in developed regions such as North America and Europe
  • Of the different therapies, Transcranial Magnetic Stimulator and Fischer Wallace Stimulator are the largest revenue-generating segment, recorded over USD 1,500 million revenue collectively throughout the study period.
  • In terms of indications, Major Depressive Disorder (MDD), and Obsessive-Compulsive Disorder (OCD) amounted to the largest revenue generating segment. MDD indicative anxiety problem is one of the highest affected condition among the young population.
  • The industry is fragmented in nature. Companies such as Eli Lily and Company, Pfizer, Inc., AstraZeneca plc, H. Lundbeck and GlaxoSmithKline plc are leading players in this industry, accounted for more than 60% share of the global market revenue.
  • Strategic initiatives to expand their presence in developing regions coupled with a huge investment in research activities to develop effective therapeutics or therapies helped these players to sustain in this market.
  • For instance, in September 2016, Pfizer, Inc. introduced “Moodivator” app to help encourage, motivate and support people with depression. This app includes simple features such as goal setting and mood tracking that leverage best principle in managing depression


  • The report presents a macro and micro-level outlook regarding the industry. Thus, it becomes easy for our clients to perceive the business landscape and take a glimpse of their own standing in it.
  • A thorough analysis of relevant statistical data to estimate the market paradigms
  • Exceptional understanding of region and country-specific markets. The report will answer some of the toughest questions regarding the market shares, sizes, forecasts segmentations, and growth specific to the countries.
  • Well-designed strategic framework analyzes the market movements including regional expansion, mergers & acquisitions, and new product developments

The scope of this report covers the market by its major segments, which include as follows:

Market Segmentation


  • Selective Serotonin Reuptake Inhibitors (SSRIs)
  • Tricyclic Antidepressants (TCAs)
  • Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
  • Monoamine oxidase inhibitors (MAOIs)
  • Anticonvulsants
  • Others


  • Transcranial Magnetic Stimulator
  • Electroconvulsive Therapy (ECT)
  • Cognitive Behaviour Therapy (CBT)
  • Fischer Wallace Stimulator
  • Others


  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • Rest of Europe
  • Asia Pacific
    • India
    • China
    • Rest of APAC
  • Rest of the World
    • Middle East and Africa
    • Latin America

Why AnalystView



Trusted Partnership

We strive to become one of the trusted partner of our client by offering value added services and concrete research data.


Tailor Made Solutions

From single reports and data downloads to enterprise subscriptions to custom consultancy, we can base our precise solutions round our client’s exact needs.

Turnaround Time

Our analyst aims to provide research studies in quickest turnaround time and in a much cost effective manner.


Data Accuracy And Reliablity

We utilize a mix of primary, secondary research, and machine learning algorithms to generate accurate and comprehensive data about market size and revenue forecasts.

Competitive Pricing

We offer most competitive pricing policy across the research industry

Client Testimonials


Asia Pacific based Chemical Industry (Privacy Requested)

Thanks AnalystView for putting a great team to work on our research projects. It was a smooth transition of knowledge and delivery was seamless. We are keen to work with you on our upcoming projects. Thank you once again for the professional attitude your team has demonstrated.

CEO, Europe based Digital Media Company (Privacy Requested)

We had confusion after receiving the final data sheet of report. As per some preliminary we already have, we believe the market is over estimated.. However, after string of calls with analyst, we found their final research analysis was methodologically sound and their work to be very professional and up […]

Managing Director, Chemical based Company, Asia Pacific (Privacy Requested)

We are happy with the way the AnalystView member understood the brief and went about executing our research project.

U.S. Headquartered Medical Device Company (Privacy Requested)

AnalystView team has done brand assessment study for blood glucose monitoring devices market, in which we want enter into….We were very impressed not only by their research skills but also by their understanding of issues relevant to our requirements…!!

Vice President, Petrochemical Firm based in China (Privacy Requested)

It was a pleasure assigning project to AnalystView; they are reliable, fast and friendly. Highly recommend this company for research workJGood stuff!

US based healthcare service provider (Privacy Requested)

Frankly, we didn’t expect much comprehensive data for the report we purchased. To be surprised, I must say the report we received was very nicely executed….It contains all the information we are looking for and satisfied with the quality of the report. Thank you team

Europe based Chemical Industry (Privacy Requested)

Just wanted to say massive thanks for all the help from the AnalystView team. We purchased two reports one is Food Safety Testing report and another one is Enzyme market. These reports have helped us build a sound knowledge base of our business segments and have taken our business to […]

Why Choose Us


We devise research report with quality data:

Combined with an in-depth knowledge of the current industry and a sharp analytical mind, AnalystView serve our customer accurate research in accordance with a constantly evolving industry.

We work with businesses just like yours: 

AnalystView committed to making a positive difference for our clients. This means whatever you demand, chances are we already have experience with something similar.

Share This